Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Another 8 items receive concessionary prices for April

The Department of Health and Social Care (DH) and the National Assembly for Wales have agreed concessionary prices for a further eight items for April 2018 prescriptions.

An initial 13 items received concessionary prices on April 20, followed by a further 15 items in a separate announcement last week.

Commenting on the latest prices, the Pharmaceutical Services Negotiating Committee said last Friday (April 27) that it "is still working with the DH to agree further concessionary prices on other drugs reported to be unavailable at the stated April 2018 drug tariff price".

Drug
Strength
Form
Price
Digoxin
62.5 microgram
tablets (28)
£1.55
Digoxin
125 microgram
tablets (28)
£1.50
Digoxin
250 microgram
tablets (28)
£1.55
Glimepiride
3mg
tablets (30)
£5.10
Irbesartan
300mg
tablets (28)
£6.97
Mirtazapine
30mg
orodispersible tablets (30)
£1.35
Topiramate
100mg
tablets (60)
£17.00
Venlafaxine
37.5mg
tablets (56)
£3.20

Do these prices reflect the ones you have paid in April so far?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD009294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel